Literature DB >> 9464831

Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines.

G B Lipford1, T Sparwasser, M Bauer, S Zimmermann, E S Koch, K Heeg, H Wagner.   

Abstract

Certain bacterial immunostimulatory (i.s.) DNA sequences containing unmethylated CpG motifs stimulate antigen-presenting cells (APC) to express a full complement of costimulatory molecules and to produce cytokines including interleukin (IL)-12 and tumor necrosis factor (TNF)-alpha. While IL-12 is key to their T helper cell (Th)1-promoting adjuvant activity, secretion of toxic levels of TNF-alpha is harmful in that it promotes toxic shock. Given the beneficial as well as harmful consequences of i.s. DNA, we investigated the possibility of identifying DNA sequences, i.e. CpG oligodeoxynucleotides (ODN) which differentially activate IL-12 versus TNF-alpha cytokine production in APC. Here, we describe an i.s. DNA sequence with these characteristics. While its potential to induce IL-12 is preserved, its ability to trigger TNF-alpha release is strongly curtailed both in vitro and in vivo. I.s. DNA could be segregated into lethal and non-lethal in a mouse toxic shock model. The non-toxic i.s. DNA was useful as an adjuvant, thus allowing cytotoxic T cell responses to the soluble protein ovalbumin and conferring a resistant Th 1 phenotype to BALB/c mice lethally infected with Leishmania major. This i.s. CpG motif may thus be prototypic for a useful immunostimulating DNA sequence that lacks harmful side effects.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9464831     DOI: 10.1002/eji.1830271242

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  46 in total

Review 1.  Introduction to immunostimulatory DNA sequences.

Authors:  J Van Uden; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

Review 2.  Rescue of B cells from apoptosis by immune stimulatory CpG DNA.

Authors:  A M Krieg; A K Yi
Journal:  Springer Semin Immunopathol       Date:  2000

Review 3.  Mechanisms of immune stimulation by bacterial DNA.

Authors:  D S Pisetsky
Journal:  Springer Semin Immunopathol       Date:  2000

Review 4.  Activation of the innate immune system by CpG oligodeoxynucleotides: immunoprotective activity and safety.

Authors:  D M Klinman; S Kamstrup; D Verthelyi; I Gursel; K J Ishii; F Takeshita; M Gursel
Journal:  Springer Semin Immunopathol       Date:  2000

Review 5.  DNA-Based Biomaterials for Immunoengineering.

Authors:  Midori Maeda; Taisuke Kojima; Yang Song; Shuichi Takayama
Journal:  Adv Healthc Mater       Date:  2018-12-05       Impact factor: 9.933

6.  Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes.

Authors:  Malgorzata Gierynska; Uday Kumaraguru; Seong-Kug Eo; Sujin Lee; Arthur Krieg; Barry T Rouse
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

7.  DNA activates human immune cells through a CpG sequence-dependent manner.

Authors:  M Bauer; K Heeg; H Wagner; G B Lipford
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

8.  CpG motifs in Porphyromonas gingivalis DNA stimulate interleukin-6 expression in human gingival fibroblasts.

Authors:  A Takeshita; K Imai; S Hanazawa
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

9.  CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation.

Authors:  H Häcker; H Mischak; T Miethke; S Liptay; R Schmid; T Sparwasser; K Heeg; G B Lipford; H Wagner
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

10.  Translocation of bacterial DNA from Gram-positive microorganisms is associated with a species-specific inflammatory response in serum and ascitic fluid of patients with cirrhosis.

Authors:  R Francés; J M González-Navajas; P Zapater; C Muñoz; R Caño; S Pascual; F Santana; D Márquez; M Pérez-Mateo; J Such
Journal:  Clin Exp Immunol       Date:  2007-09-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.